Immix Biopharma Investor Presentation Deck

IMMX: Autoimmune CAR-T Company with 73 patients dosed to-date NXC-201 FDA Investigational New Drug (IND) Application Already Cleared 1 2 3 4 5 6 First CAR-T, NXC-201, in AL Amyloidosis Expanding into Additional Autoimmune indications First "single-day CRS" CAR-T NXC-201 n=73 patients across 11 peer-reviewed publications First CAR-T Overcoming Neurotoxicity IMX-110 - promising results in colorectal cancer with 30 patients dosed ● ● ● . ●●● IMMIX S BIOPHARMA 100% overall response rate in relapsed/refractory AL amyloidosis ($3bn market) No drugs approved in relapsed/refractory AL amyloidosis today (29,712 U.S. patient prevalence) BCMA CAR-Ts are not created equal: NXC-201 designed for high activity in AL Amyloidosis NXC-201 expanding into additional autoimmune indications - more than $25 bn combined annual market size NXC-201: first "single-day CRS" CAR-T (median day 1 onset) enables patients to return home 80% faster 95% overall response rate in relapsed/refractory multiple myeloma ($18bn market) 2 Presentations (1 Oral) at 2023 American Society of Hematology (ASH) 65th Meeting Mature dataset: American Society of Cell and Gene Therapy, Haematologica, other publications Precedents for open-label, single-arm FDA approvals at ~100 patient dataset - Carvykti, Abecma -10-20x potential increase in CAR-T addressable market through wider hospital availability -5x potential hospital per-bed revenue increase by reducing CAR-T hospitalization time Overcoming neurotoxicity allows expansion into: AL Amyloidosis, autoimmune, others 75% tumor shrinkage at 2 months in stage 4 MSS relapsed/refractory colorectal cancer ($27 billion market) 4 months median progression-free survival in soft tissue sarcoma ($3bn market), median 7 prior lines of therapy 3

View entire presentation